Edition:
India

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

1.89USD
1:50am IST
Change (% chg)

$-0.09 (-4.55%)
Prev Close
$1.98
Open
$2.00
Day's High
$2.00
Day's Low
$1.80
Volume
69,170
Avg. Vol
104,191
52-wk High
$2.82
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM.ORION ALLOWS PATIENTS MORE TIMELY ACCESS TO MEDICAL DEVICES BY EXPEDITING DEVELOPMENT, ASSESSMENT, REVIEW .FDA HAS GRANTED EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION CORTICAL VISUAL PROSTHESIS SYSTEM​.  Full Article

Second Sight Medical Products reports Q3 loss per share $0.12
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Second Sight Medical Products Inc :Second sight reports third quarter 2017 financial results.Q3 loss per share $0.12.Q3 sales $1.6 million versus $1.2 million.Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11.  Full Article

Second Sight receives FDA approval to begin first Orion human clinical study
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Second Sight Medical Products Inc :Second Sight receives full FDA approval to begin first Orion human clinical study.Second sight-‍completed additional device testing, addressed remaining questions requested by FDA in prior conditional approval announced on Aug 28.Second Sight Medical Products Inc - ‍approval for Orion human clinical study allows two U.S. Sites to enroll up to five total patients​.  Full Article

Second Sight Medical Products files for mixed shelf of upto $100 mln‍​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Second Sight Medical Products Inc :Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​.  Full Article

Second sight Q2 non-GAAP loss per share $0.17 excluding items
Friday, 29 Jul 2016 

Second Sight Medical Products Inc : Q2 non-GAAP loss per share $0.17 excluding items . Second sight reports second quarter 2016 financial results . Q2 loss per share $0.23 .Q2 sales $1.0 million versus $2.7 million.  Full Article

Second Sight announces agreements to bring ARGUS II retinal prosthesis to Taiwan and Iran
Friday, 29 Jul 2016 

Second Sight Medical Products Inc :Second Sight announces two exclusive distribution agreements to bring the ARGUS II retinal prosthesis to Taiwan and Iran.  Full Article

Second Sight sets record date for rights offering
Tuesday, 10 May 2016 

Second Sight Medical : Under rights offering will distribute one non-transferable subscription right for each share of common stock held by shareholder . Each right will entitle holder to invest $0.55 for each share of common stock owned as of record date . Subscription price will equal lesser of $4.25per share or 85% of nasdaq closing price on close of subscription period on may 31 . Plans to use proceeds to continue funding ongoing post-market clinical study of argus ii retinal prosthesis systems . Plans to continue funding ongoing development of orion i visual cortical prosthesis .1 registration statement for rights offering to shareholders and sets record date.  Full Article

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM